Glenn Pierce serves as entrepreneur-in-residence at Third Rock Ventures, having joined the company in 2016 after more than 30 years of research and development experience working with biotechnology companies. He retired from Biogen in 2014, where he most recently served as Chief Medical Officer leading the hematology, cell and gene therapies division. At Biogen, Dr. Pierce spearheaded the initiation of the Humanitarian Aid Collaboration with the World Federation of Hemophilia (WFH), and My Life Our Future, a population-wide genotyping and genomic biobank initiative. Prior to Biogen, he served in small, large, public and private biotech/biopharma firms, including Bayer, Inspiration, Avigen, Selective Genetics and Amgen in the areas of tissue regeneration and hematology. Dr. Pierce is the co-author of more than 150 scientific papers and received more than15 patents. He served on the Medical and Scientific Advisory Council, the board of directors and was president of the board of the National Hemophilia Foundation during a span of two decades. Dr. Pierce also served on the Blood Products Advisory Committee at the FDA and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. He currently serves on the board of directors of the World Federation of Hemophilia and Global Blood Therapeutics. Dr. Pierce received an Doctor of Medicine and a Doctor of Philosophy in Immunology, both from Case Western Reserve University in Cleveland, and completed his postgraduate training in pathology and hematology research at Washington University in St. Louis.

science